Robert Roskoski Jr.
Robert Roskoski Jr. is the Scientific Director and President of the Blue Ridge Institute for Medical Research.[1]
Education
Roskoski studied chemistry at Bowling Green State University, receiving a B.S. degree in 1961. He received an M.D. in 1964 and a Ph.D. in 1968 from the University of Chicago. His doctoral adviser was Donald F. Steiner, the discoverer of proinsulin.[2] Roskoski was in the medical corps of the United States Air Force. Later, he became a Senior Investigator at the U.S. Air Force School of Aerospace Medicine at Brooks Air Force Base in San Antonio. He subsequently performed postdoctoral studies at the Rockefeller University under the tutelage of Fritz Lipmann from 1969 to 1972.[3]
Research and career
Dr. Robert Roskoski did research on the classification of small molecule protein kinase inhibitors that are used in the treatment of several cancers and he also developed the Gold Standard procedure for the measurement of Protein Kinase Enzyme Activity. His research interests include Protein kinase structure and function, Cancer chemotherapy, and Signal transduction.[4][5][6]
He studied protein kinase structure and function and signal transduction.[7][8] He also founded the Blue Ridge Institute for Medical Research in Horse Shoe, North Carolina in 2006. Research at the institute focuses on FDA-approved protein kinase inhibitors and monitoring extramural NIH grant support.[1][9][10][11][12][13][14]
Awards and honors
Dr. Robert Roskoski received the NIH Postdoctoral membership and NIH Special postdoctoral membership. From 1991 to 2006, he was the Fred G. Brazda Professor of Biochemistry at LSU Health Sciences Center in New Orleans.[15]
Publications
- Roskoski R Jr. (1983) Assays of protein kinase. Methods in Enzymology 99, 3–6.[16]
- Roskoski R Jr. (2005) Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys. Res. Commun. 331, 1–14.[17]
- Roskoski R Jr. (2007) Vascular endothelial growth factor (VEGF) signalling in tumor progression. Crit. Rev. Oncol. Hematol. 62, 179–213.[18]
- Roskoski R Jr. (2012) ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol. Res. 66, 105–143.[19]
- Roskoski R Jr. (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 79, 34–74.[20]
- Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 2015;100:1–23.[21]
- Roskoski R Jr. (2016) Classification of small molecule inhibitors based upon the structures of their drug enzyme complexes. Pharmacol. Res. 103, 26–48.[22]
External Links
Robert Roskoski Jr. on Google Scholar
References
- ↑ 1.0 1.1 "Robert Roskoski Jr. MD, PhD". www.brimr.org. Retrieved 2022-01-05.
- ↑ Polonsky, Kenneth S.; Rubenstein, Arthur H. (2015). "Donald F. Steiner, MD, 1930–2014". Diabetologia. 58 (3): 419–421. doi:10.1007/s00125-015-3495-x. ISSN 0012-186X. PMC 4320298. PMID 25617020.
- ↑ "Fritz Lipmann, Hans Krebs, Francis Crick, Robert Roskoski Jr., Rockefeller University, Photos". www.brimr.org. Retrieved 2022-01-05.
- ↑ Roskoski, Robert (2012-08-01). "ERK1/2 MAP kinases: Structure, function, and regulation". Pharmacological Research. 66 (2): 105–143. doi:10.1016/j.phrs.2012.04.005. ISSN 1043-6618. PMID 22569528.
- ↑ Roskoski, Robert (2015-10-01). "A historical overview of protein kinases and their targeted small molecule inhibitors". Pharmacological Research. 100: 1–23. doi:10.1016/j.phrs.2015.07.010. ISSN 1043-6618. PMID 26207888.
- ↑ Schoepfer, Joseph; Jahnke, Wolfgang; Berellini, Giuliano; Buonamici, Silvia; Cotesta, Simona; Cowan-Jacob, Sandra W.; Dodd, Stephanie; Drueckes, Peter; Fabbro, Doriano; Gabriel, Tobias; Groell, Jean-Marc (2018-09-27). "Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1". Journal of Medicinal Chemistry. 61 (18): 8120–8135. doi:10.1021/acs.jmedchem.8b01040. ISSN 0022-2623. PMID 30137981. Unknown parameter
|s2cid=ignored (help) - ↑ Roskoski, Robert (2005-11-11). "Signaling by Kit protein-tyrosine kinase—The stem cell factor receptor". Biochemical and Biophysical Research Communications. 337 (1): 1–13. doi:10.1016/j.bbrc.2005.08.055. ISSN 0006-291X. PMID 16129412.
- ↑ Roskoski, Robert (2014-01-01). "The ErbB/HER family of protein-tyrosine kinases and cancer". Pharmacological Research. 79: 34–74. doi:10.1016/j.phrs.2013.11.002. ISSN 1043-6618. PMID 24269963.
- ↑ Noble, Paige; Eyck, Patrick Ten; Jr, Robert Roskoski; Jackson, J. Brooks (2020-06-01). "NIH funding trends to US medical schools from 2009 to 2018". PLOS ONE. 15 (6): e0233367. Bibcode:2020PLoSO..1533367N. doi:10.1371/journal.pone.0233367. ISSN 1932-6203. PMC 7263845 Check
|pmc=value (help). PMID 32480400 Check|pmid=value (help). - ↑ Parslow, Tristram G.; Roskoski, Robert (2021-12-23). "A Primer on BRIMR: Understanding the Rankings of NIH Support from the Blue Ridge Institute for Medical Research". The American Journal of Pathology. 192 (3): 392–394. doi:10.1016/j.ajpath.2021.12.004. ISSN 0002-9440. PMC 8895421 Check
|pmc=value (help). PMID 34954208 Check|pmid=value (help). Unknown parameter|pmc-embargo-date=ignored (help); Unknown parameter|s2cid=ignored (help) - ↑ "psych.uic.edu". Unknown parameter
|url-status=ignored (help) - ↑ Patel, Parth A.; Gopali, Rhea; Reddy, Anvith; Patel, Kajol K. (2021-11-01). "National Institutes of Health Funding Trends to Ophthalmology Departments at U.S. Medical Schools". Seminars in Ophthalmology. 36 (5–6): 384–391. doi:10.1080/08820538.2021.1998557. ISSN 0882-0538. PMC 8328867 Check
|pmc=value (help). PMID 33634726 Check|pmid=value (help). - ↑ Thompson, Alyssa M.; Price, Kyla N.; Atluri, Swetha; Yee, Danielle; Hsiao, Jennifer L.; Shi, Vivian Y. (2021-09-01). "Gender gaps in National Institutes of Health dermatology grant recipients". International Journal of Women's Dermatology. 7 (4): 441–444. doi:10.1016/j.ijwd.2021.01.023. ISSN 2352-6475. PMC 8484991 Check
|pmc=value (help). PMID 34632037 Check|pmid=value (help). - ↑ "MSU OBGYN ranked 7th nationally in NIH funding by Blue Ridge Institute of Medical Research". rdsp.canr.msu.edu. Retrieved 2022-01-05.
- ↑ "medschool.lsuhsc.edu" (PDF). Unknown parameter
|url-status=ignored (help) - ↑ Roskoski, Robert (1983-01-01), "Assays of protein kinase", Methods in Enzymology, Hormone Action Part F: Protein Kinases, Academic Press, 99: 3–6, doi:10.1016/0076-6879(83)99034-1, ISBN 9780121819996, PMID 6316096, retrieved 2022-01-05
- ↑ Roskoski, Robert (2005-05-27). "Src kinase regulation by phosphorylation and dephosphorylation". Biochemical and Biophysical Research Communications. 331 (1): 1–14. doi:10.1016/j.bbrc.2005.03.012. ISSN 0006-291X. PMID 15845350.
- ↑ Roskoski, Robert (2007-06-01). "Vascular endothelial growth factor (VEGF) signaling in tumor progression". Critical Reviews in Oncology/Hematology. 62 (3): 179–213. doi:10.1016/j.critrevonc.2007.01.006. ISSN 1040-8428. PMID 17324579.
- ↑ Roskoski, Robert (2012-08-01). "ERK1/2 MAP kinases: Structure, function, and regulation". Pharmacological Research. 66 (2): 105–143. doi:10.1016/j.phrs.2012.04.005. ISSN 1043-6618. PMID 22569528.
- ↑ Roskoski, Robert (2014-01-01). "The ErbB/HER family of protein-tyrosine kinases and cancer". Pharmacological Research. 79: 34–74. doi:10.1016/j.phrs.2013.11.002. ISSN 1043-6618. PMID 24269963.
- ↑ Roskoski, Robert (2015-10-01). "A historical overview of protein kinases and their targeted small molecule inhibitors". Pharmacological Research. 100: 1–23. doi:10.1016/j.phrs.2015.07.010. ISSN 1043-6618. PMID 26207888.
- ↑ Roskoski, Robert (2016-01-01). "Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes". Pharmacological Research. 103: 26–48. doi:10.1016/j.phrs.2015.10.021. ISSN 1043-6618. PMID 26529477.
This article "Robert Roskoski Jr." is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Robert Roskoski Jr.. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
